Staphylococcus aureus urinary tract bacteriuria: single-institutional antibiotic susceptibility trends over a decade
Objectives: Methicillin resistant Staphylococcus aureus (MRSA) is a troublesome pathogen which is difficult for clinicians to treat. The purpose of this surveillance program is to assess the prevalence of MRSA urinary tract infections and determine risk factors for methicillin resistance in adults amongst urinary isolates of SA and to describe the antibiotic susceptibilities to guide empirical therapy.
Methods: From 2005 through to 2014, we retrospectively reviewed urine cultures recorded in a laboratory database at a university hospital in Cambridge, UK. Susceptibility testing was performed by BSAC (British Society of Antimicrobial Chemotherapy) disc diffusion testing and reported for fluoroquinolones, gentamicin, nitrofurantoin, linezolid, trimethoprim and vancomycin. Samples were denoted “MRSA” if they were resistant to oxacillin or cefoxitin.
Results: In total, 690 cultures were positive for SA, of which 293 (42.5%) were methicillin resistant. The number of SA bacteriuria decreased from around 100 per year to 40 per year. The proportion demonstrating methicillin resistance decreased from around 60% to around 20%. Both methicillin-sensitive Staphylococcus aureus (MSSA) and MRSA isolates were susceptible to vancomycin and nitrofurantoin. MRSA isolates demonstrated some increased resistance to trimethoprim and gentamicin and greatly increased resistance to fluoroquinolones. Urinary catheterization and increasing age were risk factors for methicillin resistance.
Conclusion: The incidence of SA and MRSA bacteriuria decreased during the study period. A high degree of resistance to fluoroquinolones was observed in MRSA compared to MSSA. Analysis of antibiotic susceptibility profiles suggests nitrofurantoin and trimethoprim may be useful in treating uncomplicated MSSA and MRSA urinary tract infections without concurrent bacteremia.
1. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183 Suppl 1:S1-4. doi: 10.1086/318850. PubMed PMID: 11171002.
2. Grude N, Tveten Y, Kristiansen BE. Urinary tract infections in Norway: bacterial etiology and susceptibility. A retrospective study of clinical isolates. Clin Microbiol Infect. 2001;7(10):543-7. PubMed PMID: 11683794.
3. Wagenlehner FME, Niemetz AH, Weidner W, Naber KG. Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994-2005. International journal of antimicrobial agents. 2008;31 Suppl 1:S25-34.
4. Baraboutis IG, Tsagalou EP, Lepinski JL, Papakonstantinou I, Papastamopoulos V, Skoutelis AT, et al. Primary Staphylococcus aureus urinary tract infection: the role of undetected hematogenous seeding of the urinary tract. European journal of clinical microbiology & infectious diseases. 2010;29(9):1095-101.
5. Choi SH, Lee SO, Choi JP, Lim S, Chung JW, Jeong JY, et al. The clinical significance of concurrent Staphylococcus aureus bacteriuria in patients with S. aureus bacteremia. The Journal of infection. 2009;59(1):37-41.
6. Chihara S, Popovich K, Weinstein R, Hota B. Staphylococcus aureus bacteriuria as a prognosticator for outcome of Staphylococcus aureus bacteremia: a case-control study. BMC infectious diseases. 2010;10:225.
7. Huggan PJ, Murdoch DR, Gallagher K, Chambers ST. Concomitant Staphylococcus aureus bacteriuria is associated with poor clinical outcome in adults with S. aureus bacteraemia. Journal of hospital infection. 2008;69(4):345-9.
8. Routh J, Alt A, Ashley R, Kramer S, Boyce T. Increasing prevalence and associated risk factors for methicillin resistant Staphylococcus aureus bacteriuria. The Journal of urology. 2009;181(4):1694-8.
9. Al Mohajer M, Musher D, Minard C, Darouiche R. Clinical significance of Staphylococcus aureus bacteriuria at a tertiary care hospital. Scandinavian journal of infectious diseases. 2013;45(9):688-95.
10. Shurland S, Zhan M, Bradham D, Roghmann M-C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infection control and hospital epidemiology. 2007;28(3):273-9.
11. Muder R, Brennen C, Rihs J, Wagener M, Obman A, Stout J, et al. Isolation of Staphylococcus aureus from the urinary tract: association of isolation with symptomatic urinary tract infection and subsequent staphylococcal bacteremia. Clinical infectious diseases. 2006;42(1):46-50.
12. Sheth S, DiNubile MJ. Clinical significance of staphylococcus aureus bacteriuria without concurrent bacteremia. Clinical infectious diseases. 1997;24(6):1268-9.
13. Brown DFJ, Edwards D, Hawkey P, Morrison D, Ridgway G, Towner K, et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). Journal of antimicrobial chemotherapy. 2005;56(6):1000-18.
14. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.
15. Sorlozano A, Jimenez Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez Brocal A, Miranda Casas C, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. American journal of infection control. 2014;42(10):1033-8.
16. Zhanel G, Hisanaga T, Laing N, DeCorby M, Nichol K, Weshnoweski B, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). International journal of antimicrobial agents. 2006;27(6):468-75.
17. Guirguitzova B, Chankova D, Zozikov B. [Staphylococci as uropathogens-frequency of isolation in hospitalized patients and sensitivity to antimicrobial agents]. Ann Urol (Paris). 2002;36(5):341-7.
18. Schneeberger C, Holleman F, Geerlings S. Febrile urinary tract infections: pyelonephritis and urosepsis. Current opinion in infectious diseases. 2016;29(1):80-5.
19. Yasmin M, El Hage H, Obeid R, El Haddad H, Zaarour M, Khalil A. Epidemiology of bloodstream infections caused by methicillin-resistant Staphylococcus aureus at a tertiary care hospital in New York. American journal of infection control. 2016;44(1):41-6.
20. Grayson ML, Russo P, Cruickshank M, Bear J, Gee C, Hughes C, et al. Outcomes from the first 2 years of the Australian National Hand Hygiene Initiative. Medical journal of Australia. 2011;195(10):615-9.
21. Mendes R, Sader H, Flamm R, Farrell D, Jones R. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrobial agents and chemotherapy. 2014;58(5):2921-4.
22. Jones R, Sader H, Flamm R. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304-7.
23. !!! INVALID CITATION !!! (16-18).
24. Therapeutic Guidelines Limited. Severe sepsis and septic shock: Staphylococcus aureus. ETG complete [Internet]. 2014 08/05/2015. Available from: http://www.tg.org.au/.
25. Liu C, Bayer A, Cosgrove S, Daum R, Fridkin S, Gorwitz R, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical infectious diseases. 2011;52(3):e18-55.
26. Felten A, Grandry B, Lagrange P, Casin I. Evaluation of three techniques for detection of low-level methicillin-resistant Staphylococcus aureus (MRSA): a disk diffusion method with cefoxitin and moxalactam, the Vitek 2 system, and the MRSA-screen latex agglutination test. Journal of clinical microbiology. 2002;40(8):2766-71.
27. Skov R, Smyth R, Clausen M, Larsen AR, Frimodt Moller N, Olsson Liljequist B, et al. Evaluation of a cefoxitin 30 microg disc on Iso-Sensitest agar for detection of methicillin-resistant Staphylococcus aureus. Journal of antimicrobial chemotherapy. 2003;52(2):204-7.